Howard ‘Jack’ West, MD, Executive Director of Employer Strategy; Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research at the City of Hope speaks about ASCO 2021 Top 5 Abstracts in Lung Cancer.
Link to Abstract 8500- IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
https://meetinglibrary.asco.org/record/195950/abstract
Link to Abstract 8517 – Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.
https://meetinglibrary.asco.org/record/196544/abstract
Link to Abstract 9006 – Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
https://meetinglibrary.asco.org/record/196820/abstract
Link to Abstract 9007 – Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
https://meetinglibrary.asco.org/record/196836/abstract
Link to Abstract 9003 – Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.
https://meetinglibrary.asco.org/record/196931/abstract
Link to Abstract 9004 – Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.